Rodricks and Lumpkin argue that 1,3-dimethylamylamine (DMAA) does not possess amphetamine-like effects, is found in geranium, and has been documented to be safe. These are all inaccurate characterizations of the literature.

DMAA is a pharmaceutical patented by Eli Lilly & Co to possess the desirable properties of both ephedrine and amphetamine. An indirect sympathomimetic amine, DMAA has both vasoconstrictive properties and cardiovascular effects.